Related Experiment Video

Updated: Aug 6, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

A Quarter Century of Transformation: Integrating Molecular Stratification and Immune Modulation Across the Continuum

Amin H Nassar1, Jad Halawi2, Roy S Herbst1

  • 1Division of Medical Oncology, Yale Cancer Center, New Haven, CT.

Cancer Journal (Sudbury, Mass.)
|July 24, 2026
PubMed

Insights

Recent advances in non-small-cell lung cancer (NSCLC) treatment include targeted therapies and immunotherapy. These innovations improve survival across all stages of NSCLC, from early to metastatic disease.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Non-small-cell lung cancer (NSCLC) treatment has evolved significantly over 25 years.
  • Key drivers include molecular profiling, targeted therapies, CT screening, and immunotherapy.

Purpose of the Study:

  • To review pivotal therapeutic advances in NSCLC across all disease stages.
  • To identify needs for better biomarkers for treatment selection and intensity.
  • To outline emerging therapeutic strategies in NSCLC.

Main Methods:

  • Literature review of therapeutic advances in NSCLC.
  • Analysis of genomic profiling, targeted agents, and immunotherapy.
  • Examination of perioperative, consolidation, and adjuvant strategies.

Main Results:

  • Targeted therapies improve survival in oncogene-driven metastatic and resectable NSCLC.
  • Immune checkpoint inhibitors are now first-line for many NSCLC patients and used in perioperative settings.
  • Tyrosine kinase inhibitors enhance precision oncology in early-stage EGFR- and ALK-driven NSCLC.

Conclusions:

  • Therapeutic landscape of NSCLC has transformed, improving outcomes.
  • Need for refined biomarkers to guide treatment intensity and sequencing.
  • Emerging strategies include upfront combinations and ctDNA-guided adaptive therapy.
Keywords:
artificial intelligencegenomicsimmunotherapymachine learningnon–small cell lung cancertargeted therapies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.